Leerink Swann Weighs in on Aduro Biotech, Inc.’s FY2017 Earnings (ADRO)
Aduro Biotech, Inc. (NASDAQ:ADRO) – Analysts at Leerink Swann raised their FY2017 EPS estimates for Aduro Biotech in a research report issued on Wednesday. Leerink Swann analyst S. Fernandez now expects that the biotechnology company will post earnings of ($1.39) per share for the year, up from their previous forecast of ($1.51). Leerink Swann also issued estimates for Aduro Biotech’s Q4 2017 earnings at ($0.46) EPS, FY2018 earnings at ($1.21) EPS, FY2019 earnings at ($0.74) EPS and FY2020 earnings at ($1.07) EPS.
A number of other research analysts have also commented on ADRO. HC Wainwright set a $18.00 price objective on Aduro Biotech and gave the company a “buy” rating in a report on Wednesday, November 1st. BidaskClub lowered Aduro Biotech from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. Zacks Investment Research lowered Aduro Biotech from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. Canaccord Genuity set a $30.00 price objective on Aduro Biotech and gave the company a “buy” rating in a report on Thursday, August 3rd. Finally, William Blair reaffirmed an “outperform” rating on shares of Aduro Biotech in a report on Monday, October 2nd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company’s stock. Aduro Biotech currently has a consensus rating of “Buy” and a consensus price target of $19.14.
ILLEGAL ACTIVITY WARNING: “Leerink Swann Weighs in on Aduro Biotech, Inc.’s FY2017 Earnings (ADRO)” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/11/06/leerink-swann-weighs-in-on-aduro-biotech-inc-s-fy2017-earnings-adro.html.
Shares of Aduro Biotech (ADRO) opened at $7.95 on Monday. Aduro Biotech has a 12 month low of $6.01 and a 12 month high of $15.52.
Aduro Biotech (NASDAQ:ADRO) last posted its quarterly earnings results on Tuesday, October 31st. The biotechnology company reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.03). Aduro Biotech had a negative net margin of 548.92% and a negative return on equity of 39.28%. The business had revenue of $3.79 million during the quarter, compared to the consensus estimate of $4.04 million. During the same quarter last year, the company posted ($0.54) EPS. The firm’s revenue was up .0% on a year-over-year basis.
In other news, insider Jennifer Lew sold 6,600 shares of the stock in a transaction on Friday, September 1st. The stock was sold at an average price of $11.70, for a total transaction of $77,220.00. Following the sale, the insider now directly owns 49,195 shares of the company’s stock, valued at approximately $575,581.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Stephen T. Isaacs sold 40,000 shares of the stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $10.78, for a total value of $431,200.00. Following the sale, the chief executive officer now directly owns 213,921 shares in the company, valued at $2,306,068.38. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 260,334 shares of company stock worth $2,952,556. Insiders own 6.60% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in ADRO. Bank of New York Mellon Corp grew its holdings in shares of Aduro Biotech by 3.8% during the 1st quarter. Bank of New York Mellon Corp now owns 148,166 shares of the biotechnology company’s stock worth $1,593,000 after purchasing an additional 5,470 shares in the last quarter. Parametric Portfolio Associates LLC grew its holdings in shares of Aduro Biotech by 15.9% during the 1st quarter. Parametric Portfolio Associates LLC now owns 15,424 shares of the biotechnology company’s stock worth $166,000 after purchasing an additional 2,119 shares in the last quarter. American International Group Inc. grew its holdings in shares of Aduro Biotech by 7.1% during the 1st quarter. American International Group Inc. now owns 21,840 shares of the biotechnology company’s stock worth $235,000 after purchasing an additional 1,447 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Aduro Biotech by 2.1% during the 1st quarter. Vanguard Group Inc. now owns 2,382,916 shares of the biotechnology company’s stock worth $25,617,000 after purchasing an additional 48,840 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Aduro Biotech by 6.0% during the 1st quarter. Geode Capital Management LLC now owns 262,809 shares of the biotechnology company’s stock worth $2,825,000 after purchasing an additional 14,946 shares in the last quarter. 34.01% of the stock is currently owned by institutional investors.
Aduro Biotech Company Profile
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.